>Rare diseases are a growth driver - Recordati reported on Friday during trading its figures for Q3 2024. Sales over the period are 2.8% below forecasts at € 557.4m (+9% y-o-y). We highlight: i/ growth momentum still driven by the rare diseases segment (+14.5% cc) for 9M, with business continuing to benefit from endocrinology (+36%) and oncology (+17%); ii/ growth in the SPC franchise is still robust at 9% (+6.5% cc), but more impacted than expected by the Cough&Cold ...
>Les maladies rares en locomotive de la croissance - Recordati a publié vendredi en séance ses chiffres au titre du T3 2024. Les ventes sur la période ressortent 2.8% inférieures aux attentes à 557.4 M€ (+9% yoy). Nous soulignons i/ une dynamique de croissance toujours tirée par le segment des maladies rares (+14,5% tcc) sur les 9 premiers mois, l'activité continue de bénéficier de l'endocrinologie (+36%) et de l'oncologie (+17%), ii/ la croissance de la franchise SPC...
In today's Morning Views publication we comment on developments of the following high yield issuers: Nexans, Recordati, TeamSystem, Stada, CMA CGM, Nexi, Vedanta Resources, Fedrigoni, Modulaire, TI Fluid Systems, Iceland Foods, United Group, Standard Profil, Selecta, Italmatch Chemicals
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY...
In today's Morning Views publication we comment on developments of the following high yield issuers: Recordati, Teva, Novelis, Bombardier, Selecta, Hapag-Lloyd, Italmatch Chemicals, Kem One, Cirsa, Nexans, ASK Chemicals, Borr Drilling, Encore Capital (formerly Cabot)
Elis has ended discussions with Vestis and UniFirst Ubisoft: Tencent and the Guillemot family are said to weigh various scenarios including a buyout (Bloomberg)ZF Friedrichshafen : short-term rating pressure from Moody’s Advanz Pharma : deep-pocket Ontario Teacher’s Pension Plan steps back from potential stake>...
Elis a mis fin aux discussions avec Vestis et UniFirst Ubisoft : Tencent et la famille Guillemot réfléchiraient à différents scénarios dont un rachat de la société (Bloomberg)ZF Friedrichshafen : short-term rating pressure from Moody’s Advanz Pharma : deep-pocket Ontario Teacher’s Pension Plan steps back from potential stake >...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
>Acquisition of Enjaymo in cold agglutinin disease - Recordati on Friday announced a fresh acquisition for € 825m (+ up to € 250m in commercial milestones) with Enjaymo (sutimlimab), a monoclonal antobody developed by Sanofi in the treatment of cold agglutinin disease, a rare form of anaemia. The treatment, the only drug specifically approved in this indication, has generated sales of € 100m over the last 12 months (in the US, Europe and Japan).We see this a stra...
>Acquisition d’Enjaymo dans la maladie des agglutinines froides - Recordati a annoncé vendredi dernier une nouvelle acquisition pour 825 M€ (+ jusqu’à 250 M€ de milestones commerciaux) d’Enjaymo (sutimlimab), un anticorps monoclonal développé par Sanofi dans le traitement de la maladie des agglutinines froides, une forme d’anémie rare. Le traitement, seul produit approuvé spécifiquement dans cette indication, a généré environ 100 M€ sur les 12 derniers mois (aux Etats...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.